🇺🇸

Distress Insolvency

US SEC Filing Intelligence · 192 digests

· daily

US Corporate Distress Financial Stress SEC Filings — October 16, 2026

This batch of 10 filings is dominated by listing-compliance and distress signals rather than operating performance: seven of ten filings concern Nasdaq or NYSE deficiency notices, voluntary delisting, or delisting processes (Bridgeline Digital, Aether Holdings, CALLAN JMB, eHealth, Lucid Diagnostics, Health In Tech, Canopy Growth), while the remaining filings cover a voluntary NYSE delisting (SITE Centers), an undisclosed-reason NYSE delisting (Apollo Commercial Real Estate Finance), and a completed Chapter 11 emergence (Cumulus Media). The filings do not contain period-over-period financial comparisons, forward guidance figures, insider transaction data, or capital allocation metrics, so quantitative trend analysis is not possible from this batch; the analysis below relies on dates, thresholds, and deadlines stated in the filings. The most acute situation is CALLAN JMB, which faces a trading suspension on October 21, 2026 absent a successful Nasdaq Hearings Panel outcome after failing a $2.5M stockholders' equity requirement. A recurring theme is the April 12, 2027 Nasdaq bid-price compliance deadline shared by four companies, which will likely produce a cluster of reverse-split proposals and listing-transfer decisions. Cumulus Media's emergence, eliminating roughly $550M to $600M of debt, is the single most material restructuring outcome, though it removes the public equity instrument from the stream's view.

10 high priority 10 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 16, 2026

This quiet session contains a single in-scope filing: Cumulus Media's 8-K announcing completion of its prepackaged Chapter 11 restructuring, filed March 4, 2026 in the Southern District of Texas. The plan canceled roughly $600 million of funded debt in exchange for 100% of reorganized equity and $50 million of new convertible notes issued to former lenders, with the release citing $550 million of debt eliminated. The company is now privately owned, ending its public listing under CMLS, appointed a new Board, retained management, and amended its ABL revolver to maintain liquidity. Period-over-period operating metrics, forward guidance, insider activity, and capital allocation data were not quantified in the release, so cross-filing trend analysis is not possible from this session. The market implication is that the equity of the former public company is effectively extinguished for public holders, while the deleveraged private entity's post-emergence performance will be opaque absent future disclosures. With a single filing, no sector-wide pattern can be asserted.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 15, 2026

All three filings in this stream are Nasdaq minimum-bid-price or creditor-process disclosures, and together they paint a picture of late-stage distress concentrated in micro-cap, low-priced equities. Innovative Eyewear (LUCY) and Cyngn (CYN) both received Nasdaq Rule 5550(a)(2) deficiency notices after 30 consecutive business days below $1.00, with compliance windows ending April 7, 2027 and April 12, 2027 respectively, so near-term delisting risk is not imminent but both stocks face a reverse-split decision within roughly six months. Greenlane Holdings (GNLN) is the most severe case: four operating subsidiaries executed Florida Chapter 727 assignments for the benefit of creditors on September 30, 2026, with Miami-Dade Circuit Court jurisdiction assumed October 9, 2026, meaning an assignee is liquidating assets for creditors, and the filing flags potential claims against the parent or remaining subsidiaries. The filings provided do not include period-over-period financial comparisons, insider transaction data, capital allocation details, or forward guidance, so quantitative trend analysis is limited to what the notices themselves state. The portfolio-level pattern is clear: sub-$1 equity, dilution-prone capital structures, and a reverse split as the common cure path.

3 high priority 3 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 15, 2026

This digest covers a single enriched filing in the USA Bankruptcy & Insolvency stream: an 8-K from Greenlane Holdings, Inc. (GNLN) disclosing that four subsidiaries executed Florida Chapter 727 assignments for the benefit of creditors on September 30, 2026, with court jurisdiction assumed by the Miami-Dade Circuit Court on October 9, 2026. The filing is squarely in scope (insolvency proceedings under an ABC process) and carries high materiality (8/10) and negative sentiment. No period-over-period financial comparisons, forward-looking guidance, insider transactions, or capital allocation data were provided in the enriched payload, so cross-filing trend analysis is not possible from this stream alone. The critical development is that the assignee will liquidate assets and distribute proceeds, the assignments do not discharge subsidiary liabilities, and no consolidation or judge has yet been assigned. The prior deconsolidation of these entities and the flagged potential claims against the parent or remaining subsidiaries mean the parent's equity exposure and contingent liability profile remain unresolved.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 14, 2026

Both filings in this window are Nasdaq listing-compliance disclosures, and both fall squarely within the Corporate Distress & Bankruptcy stream's delisting scope. AMASS Brands received a new Nasdaq notice for 30 consecutive business days below $1.00 (compliance deadline April 7, 2027), layered on top of a separate market value deficiency with a January 19, 2027 deadline, indicating compounding listing stress. Netcapital Inc. cured its bid-price deficiency but remains exposed to a more serious governance problem: late FY2026 10-K and Q1 FY2027 10-Q filings, prior financial statements declared unreliable for FY2022 through FY2025, auditor resignation, and a re-audit now under way with Adeptus Partners. The enriched period-over-period, insider, forward-looking, and capital-allocation fields are not populated for either filing, so quantitative trend analysis is not possible from this data; the conclusions rest on disclosed deficiencies and deadlines. The common theme is that sub-$1 trading and filing or reporting failures are the leading distress indicators for small-cap Nasdaq issuers, and both situations carry delisting risk that is only partly time-bounded.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 13, 2026

All five filings sit squarely in the stream's distress scope (Nasdaq/NYSE delisting notices, going-concern disclosure, and balance-sheet stress), and none carries the forward-looking guidance, insider-trading, or capital-allocation enrichment the brief anticipates, so the synthesis rests mainly on the stated filing facts. The dominant theme is listing-compliance distress: three of five filings (ClearOne, Newton Golf, Equus) cite exchange deficiencies, two of which (ClearOne, Newton Golf) involve the $2.5 million minimum stockholders' equity test under Nasdaq Rule 5550(b)(1), a direct signal of capital erosion. Visium Technologies shows the clearest quantified deterioration: operating cash burn widened 122% to $(913,888), cash fell 63% to $22,212, and FY net income of $856,102 was produced entirely by a $2,923,004 debt-extinguishment gain rather than operations, while ~1.27 billion shares outstanding plus ~1.32 billion potential shares signal heavy dilution. CN Healthy Food Tech is the outlier, with a Nasdaq Panel keeping it listed under a one-year monitor after a disclosure omission regarding a CSRC filing, a governance rather than solvency issue. The near-term catalyst cluster is the October 13-20, 2026 window, when hearing-request and appeal deadlines determine whether ClearOne, Newton Golf and Equus face imminent suspension.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 09, 2026

All five filings in this stream are distress-related, centered on US exchange listing deficiencies rather than bankruptcy filings or going-concern opinions. The common thread is Nasdaq and NYSE/NYSE American continued-listing enforcement: three companies face sub-$1 bid-price or equity-related deficiencies (Streamex, Accendra Health), and three face governance or filing-compliance failures (Better Home & Finance, IT Tech Packaging), with Alaunos already at the delisting-hearing stage. Because the enriched period-over-period, insider, capital-allocation and forward-looking fields were not populated in these filings, quantitative trend comparisons are not available; the analysis therefore rests on the explicit deadlines, notice dates and materiality ratings disclosed. The most critical development is Alaunos Therapeutics (materiality 8/10), where the October 5, 2026 delisting notice for sub-$2.5M stockholders' equity is now proceeding to a Hearings Panel with a strategic-alternatives process that carries no assured outcome. IT Tech Packaging (8/10) and Better Home & Finance (7/10) also carry near-term enforcement risk, while Streamex and Accendra have the longest cure windows (to April 2027 and roughly April 2027 respectively). Portfolio-level, the pattern is distress manifesting as exchange compliance pressure well ahead of any insolvency event.

5 high priority 5 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 07, 2026

This digest covers a single filing from Greenlane Holdings, Inc., which falls squarely within the Bankruptcy & Insolvency stream. The company’s 8-K reveals that four subsidiaries made assignments for the benefit of creditors (ABCs) under Florida law, effectively transferring substantially all assets to an assignee for liquidation. This action results in deconsolidation, removing $594,573 in assets and $3,754,180 in liabilities from the balance sheet, though liabilities are not discharged. Pro forma financials show a dramatic 95% revenue decline from $4.355M to $225,000 for FY2025, while net loss improves from $85.580M to $48.117M due to the removal of subsidiary losses. Critically, the parent company received no consideration for the assignments and continues to report significant operating losses and unrealized losses on digital assets, indicating a deeply distressed financial position. The negative sentiment and high materiality (9/10) underscore a severe solvency crisis with no apparent turnaround path, making this a high-risk event for stakeholders.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 06, 2026

The October 6, 2026, corporate distress landscape is dominated by two Nasdaq compliance failures (FibroGen/Kyntra Bio and Virtuix Holdings), both receiving Staff Determinations on the same day (Sept 30, 2026) for failing to meet minimum market value and alternative financial standards. This clustering suggests a potential tightening of Nasdaq enforcement or a broader market-cap erosion among small-cap issuers. International Bancshares Corporation's voluntary delisting to the Texas Stock Exchange is a non-distress event and is excluded from further analysis. Neither distressed company provided period-over-period financial comparisons, forward guidance, or insider trading data in their 8-K filings, limiting quantitative trend analysis. The key actionable insight is the 180-day compliance window for both firms, creating a binary catalyst timeline. The lack of insider buying or capital allocation disclosures in these filings is itself a bearish signal, suggesting management is not signaling confidence through open-market purchases.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 05, 2026

The four filings reveal stark distress across US-listed companies, with two imminent delistings and one bankruptcy filing on a single day. ESS Tech faces a second NYSE delisting for failing to maintain a $15 million market cap, forcing a move to OTC markets and severely reducing liquidity. Purple Innovation received a Nasdaq non-compliance notice for failing the $15 million MVPHS threshold, with a compliance deadline that appears to contain a typo, adding uncertainty. Leslie's filed for Chapter 11 bankruptcy on September 30, 2026, securing a $90 million DIP facility to fund operations. CECO Environmental's voluntary switch from Nasdaq to the Texas Stock Exchange is the only non-distressed event, though it signals a strategic shift. No insider trading or forward-looking guidance was disclosed in any filing, limiting fundamental trend analysis. The cluster of events on September 30 and October 2, 2026, suggests macro pressures from rising rates or sector-specific headwinds are accelerating distress.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 05, 2026

Leslie's, Inc. filed for Chapter 11 bankruptcy on September 30, 2026, marking a critical inflection point for the company and the broader pool retail sector. The filing reveals a severe liquidity crisis, addressed through a $90 million debtor-in-possession (DIP) facility to fund operations during restructuring. The absence of period-over-period financial data in the filing underscores the urgency and opacity of the situation, with the company's future hinging on successful court-approved restructuring. This event signals potential distress among discretionary consumer goods retailers, particularly those with high debt loads and seasonal cash flow patterns. The DIP facility's terms, including covenants and milestones, will be key indicators of the company's restructuring trajectory. Investors should monitor the bankruptcy proceedings for asset sale opportunities and potential equity wipeout scenarios.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 02, 2026

All 8 filings in this digest signal acute distress across US-listed micro-cap companies, with 8/8 receiving delisting or deficiency notices from Nasdaq or NYSE American within a single week (September 28-October 1, 2026). The dominant theme is a liquidity crisis: 6 companies failed the $1.00 minimum bid price rule, one failed the $35M MVLS requirement, and one was delisted for low selling price. Notably, 3 companies (Amaze, Direct Digital, Healthcare Triangle) face imminent trading suspensions, with Healthcare Triangle ineligible for standard cure periods due to two reverse splits totaling 1-for-14,940—a hallmark of chronic price decay. The cluster of identical compliance deadlines (March 29, 2027) suggests a systemic wave of micro-cap distress, likely driven by sustained selling pressure and weak fundamentals. No period-over-period financial data or insider activity was disclosed in these filings, limiting quantitative trend analysis, but the absence of any bullish signals underscores the severity. The most critical near-term catalyst is Healthcare Triangle's October 8 appeal deadline, which will determine whether it faces immediate suspension. Investors should treat these as high-risk situations with limited upside, though potential reverse-split-driven compliance and OTC market transitions create speculative trading opportunities.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 01, 2026

This digest covers six US SEC filings from October 1, 2026, all within the corporate distress and bankruptcy stream. The dominant theme is a wave of Nasdaq and NYSE delisting actions, with three companies (Lantern Pharma, Gaxos.ai, Getty Images) receiving non-compliance or delisting notices due to market value, bid price, or abnormally low selling price failures. Getty Images has already been suspended and moved to the OTC market, while Lantern Pharma and Gaxos.ai have 180-day cure periods. A fourth company, SKYX Platforms, fell out of compliance due to a board member's death, triggering governance rule violations. NSTS Bancorp completed a cash merger and was voluntarily delisted, representing a clean exit. Nextdoor voluntarily transferred its listing from NYSE to Nasdaq, a non-distressed move. Period-over-period data was limited in these filings, but the concentration of delisting events signals heightened distress in small-cap and micro-cap equities, particularly in the AI and biotech sectors. Insider activity was absent across all filings, and no forward-looking guidance or capital allocation changes were disclosed, limiting trend analysis but amplifying the urgency of the compliance deadlines.

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 30, 2026

The four filings collectively paint a stark picture of distress across US-listed companies, with all four facing delisting or bankruptcy events in September 2026. Notably, three of the four (ESS Tech, Outlook Therapeutics, Petros Pharmaceuticals) are micro-cap or small-cap companies grappling with NYSE/Nasdaq listing standards, while the fourth (Leslie's) is a larger retailer executing a prearranged Chapter 11 restructuring. Period-over-period data, where available, shows no revenue growth or margin improvements, and all filings carry negative sentiment with materiality scores of 8-10/10. The most critical development is Leslie's bankruptcy, which eliminates ~$685M (90%) of funded debt and secures $150M in new capital, signaling a potential restructuring opportunity. The sector themes indicate a bifurcation: smaller biotech/industrial companies face liquidity-driven delisting risks, while larger consumer discretionary names use Chapter 11 to deleverage and streamline operations. Insider activity is notably absent across all filings, suggesting management teams are not signaling confidence through purchases. The watch list centers on appeal deadlines (ESS Tech, Outlook Therapeutics) and Leslie's emergence timeline (early 2027).

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 30, 2026

The September 30, 2026 filings mark a significant escalation in US retail and pharmaceutical distress, with both Petros Pharmaceuticals and Leslie's, Inc. announcing liquidity events that effectively end or restructure their existing equity structures. Petros Pharmaceuticals executed a General Assignment for the Benefit of Creditors (ABC), a state-law alternative to bankruptcy, resulting in an immediate liquidation event, cessation of operations, and triggering of redemption obligations on preferred stock. Leslie's filed for prearranged Chapter 11 with lender support, aiming to eliminate ~90% of its funded debt ($685M) while securing $150M in new capital and closing 76 stores. Both events are characterized by negative sentiment and maximum materiality, reflecting severe operational and balance sheet stress. The period-over-period data, while not providing specific revenue or margin figures, indicates a complete loss of going concern for Petros and a strategic deleveraging for Leslie's. The market implications are stark: equity holders in both companies face near-total value destruction, while creditors and distressed investors see opportunities in the restructuring. The filings highlight a broader theme of retail and specialty pharmaceutical companies struggling with high leverage and shifting consumer dynamics, leading to insolvency proceedings.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 29, 2026

The four filings in this intelligence stream collectively paint a picture of acute distress across a spectrum of US-listed companies, with a heavy concentration of Nasdaq non-compliance issues. The most critical development is the completed $6.3 billion take-private of Global Business Travel Group (Amex GBT), which, while a positive exit for shareholders, removes a major publicly traded entity and signals a potential trend of private equity scooping up undervalued travel-tech assets. The remaining three filings all involve Nasdaq listing deficiencies, highlighting a systemic stress point for micro-cap and pre-revenue companies. Period-over-period data, where available, shows a clear pattern of deteriorating financial health: SurgePays is fighting a bid price deficiency despite a 180-day extension, while Liminatus Pharma only regained compliance through a dilutive 1-for-50 reverse stock split, a classic sign of financial engineering rather than organic recovery. Maison Solutions is the newest entrant to the distress pool, having failed to file its annual and quarterly reports, suggesting potential accounting or operational issues. The portfolio-level theme is unmistakable: a rising tide of micro-cap companies are failing to meet basic exchange requirements, creating a high-risk environment where delisting and bankruptcy are increasingly probable outcomes for those unable to secure financing or execute a turnaround.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 28, 2026

The two filings in this digest reveal a concentrated micro-cap distress theme within the US small-cap healthcare/consumer staples space, both centered on Nasdaq listing compliance. Hain Celestial Group, a larger branded consumer company, received a transfer to the Nasdaq Capital Market and a 180-day extension to March 22, 2027, to address its bid price deficiency, while simultaneously losing its Chief Accounting Officer—a combination that signals operational and governance strain. Nexalin Technology, a micro-cap medical device maker, faces a more acute crisis with a September 28, 2026 deadline to demonstrate a $1.00 closing bid for 20 consecutive sessions and a January 4, 2027 deadline to restore $2.5M in stockholders' equity, having already received two delisting notices. Both companies exhibit negative sentiment and high materiality (8/10 and 9/10), with no positive period-over-period trends or insider buying to offset the distress. The key differentiator is the timeline: Hain has a longer runway and a more established business, while Nexalin's imminent deadlines create a binary event risk. Neither filing contains revenue, margin, or guidance data, limiting fundamental comparison, but the pattern of repeated compliance failures and executive departures suggests a broader deterioration in small-cap governance and financial health. The market implication is that these are speculative, event-driven situations where the risk of delisting and equity devaluation is elevated, but the potential for a reverse-split-driven rally or a successful equity raise creates short-term trading opportunities.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 25, 2026

This intelligence brief reveals a severe and concentrated wave of corporate distress across US-listed companies, with 8 out of 10 filings detailing active delisting threats or non-compliance with exchange listing standards. The dominant theme is a liquidity and market capitalization crisis, with companies like Silexion, SANUWAVE, Dyadic, and Fusemachines all failing to meet minimum bid price or market value thresholds. The period-over-period data, though limited in this set, points to sustained net losses and equity erosion, as seen in Southland Holdings' $248.2M stockholders' deficit and Calidi Biotherapeutics' sub-$4M equity base. A notable divergence is the voluntary, strategic transfer of Lumen Technologies to Nasdaq, which stands in stark contrast to the involuntary delistings. Insider trading activity is absent across these filings, suggesting a lack of management conviction or an inability to signal confidence. The most critical development is the immediate suspension of SilverBox Corp IV's NYSE trading, forcing it to the OTC market, while the October 2026 compliance plan deadlines for Netcapital, Southland, and Calidi create a high-stakes catalyst calendar. The market implication is clear: investors face a binary risk of total equity loss through forced delistings, with limited recovery prospects for common shareholders.

10 high priority 10 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 24, 2026

The single filing in this digest, from Beasley Broadcast Group Inc., presents a governance-related distress signal rather than a financial or operational crisis. The death of independent director Peter A. Bordes, Jr. has reduced the Audit Committee to two members, triggering non-compliance with Nasdaq's audit committee independence rule. While this is a procedural issue with a cure period extending to September 2027, it introduces near-term uncertainty regarding board composition and regulatory standing. The event is isolated and does not reflect broader sector-wide distress, but it does highlight governance fragility in a small-cap media company. No period-over-period financial trends, insider trading, capital allocation changes, or forward-looking guidance were available in this filing, limiting the depth of quantitative synthesis. The primary actionable insight is the need to monitor the company's ability to appoint a qualified independent director within the cure period, as failure could lead to delisting risk.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 23, 2026

The two filings in this digest both involve Nasdaq delistings, highlighting a concentrated distress pattern among micro-cap healthcare/tech companies facing liquidity and compliance crises. SCWorx Corp. (WORX) and Aditxt, Inc. (ADTX) have both been suspended from Nasdaq and now trade on the OTC markets, with SCWorx attempting a last-minute cure via a private placement and Aditxt facing final delisting. Neither filing provided period-over-period financial comparisons, insider trading data, forward-looking guidance, or capital allocation metrics, limiting quantitative trend analysis. The lack of insider activity and financial metrics in both cases amplifies the opacity and risk, as management has not signaled confidence through purchases or provided turnaround targets. The critical development is SCWorx's October 5, 2026 deadline to regain bid price compliance, which represents a binary catalyst for the stock. The overarching theme is that distressed micro-caps are failing to maintain Nasdaq listing standards post-reverse splits, with no visible insider support or credible recovery plans.

2 high priority 2 total filings